Intravitreal Steroids and Glaucoma

  • Yousuf Khalifa
  • Sandra M. Johnson


Intravitreal injection of pharmaceuticals has gained widespread acceptance. As the roles of inflammation and neovascularization in eye pathologies are being elucidated, the indications for intravitreal triamcinolone (IVTA) are expanding. First introduced in 1974 as a treatment for proliferative vitreoretinopathy, IVTA is currently employed in the treatment of diabetic macular edema, macular edema associated with branch and central retinal vein occlusion, exudative age-related macular degeneration, pseudophakic cystoid macular edema, and uveitic cystoid macular edema.


Macular Edema Intravitreal Injection Diabetic Macular Edema Retinal Vein Occlusion Trabecular Meshwork 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Graham OR, Peyman GA. Intravitreal injection of dexamethasone: treatment of experimentally induced endophthalmitis. Arch Ophthalmol. 1974;92:149–154.PubMedGoogle Scholar
  2. 2.
    Patelli F, Fasolino G, Raice P, et al. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina. 2005;25:840–844.CrossRefPubMedGoogle Scholar
  3. 3.
    Ozkiris A, Everklioglu C, Erkilic K, Dogan H. Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye. 2006;20:13–17.CrossRefPubMedGoogle Scholar
  4. 4.
    Bashshur ZF, Ma’luf RN, Allam S, et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol. 2004;122:1137–1140.CrossRefPubMedGoogle Scholar
  5. 5.
    Gregori NZ, Rosenfeld PJ, Puliafito CA, et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina. 2006;26(8):889–895.CrossRefPubMedGoogle Scholar
  6. 6.
    Schadlu R, Kymes SM, Apte RS. Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: effect of initial visual acuity on treatment response. Graefes Arch Clin Exp Ophthalmol. 2007;245:1667–1672.CrossRefPubMedGoogle Scholar
  7. 7.
    Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301–304.CrossRefPubMedGoogle Scholar
  8. 8.
    Benhamou N, Massin P, Haouchine B, et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol. 2003;135:246–249.CrossRefPubMedGoogle Scholar
  9. 9.
    Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112:1916–1921.CrossRefPubMedGoogle Scholar
  10. 10.
    Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681–686.CrossRefPubMedGoogle Scholar
  11. 11.
    Mason JO, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina. 2004;24:900–904.CrossRefPubMedGoogle Scholar
  12. 12.
    Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004;137:560–562.CrossRefPubMedGoogle Scholar
  13. 13.
    Chin H, Park T, Moon Y, Oh J. Difference in clearance of intravitreal triamcinolone between vitrectomized and nonvitrectomized eyes. Retina. 2005;25:556–560.CrossRefPubMedGoogle Scholar
  14. 14.
    Jonas JB. Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol. 2002;86:1450–1451.CrossRefPubMedGoogle Scholar
  15. 15.
    Kotliar K, Maier M, Bauer S, et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007;85(7):777–781.CrossRefPubMedGoogle Scholar
  16. 16.
    Chang W, Chung M. Efficacy of anterior chamber paracentesis after intravitreal triamcinolone injection. Eur J Ophthalmol. 2007;17(5):776–779.PubMedGoogle Scholar
  17. 17.
    Galor A, Margolis R, Brasil OM, et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007;114(10):1912–1918.CrossRefPubMedGoogle Scholar
  18. 18.
    Hernaez-Ortega MC, Soto-Pedre E. Use of the Honan balloon as a compression device for intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging. 2007;38(1):87–88.PubMedGoogle Scholar
  19. 19.
    Singh IP, Ahmad SI, Yeh D, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2004;138:286–287.CrossRefPubMedGoogle Scholar
  20. 20.
    Vendantham V. Intraocular pressure rise after intravitreal triamcinolone. Am J Ophthalmol. 2005;139(3):575.CrossRefGoogle Scholar
  21. 21.
    Wang YS, Friedrichs U, Eichler W, et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol. 2002;240:42–48.CrossRefPubMedGoogle Scholar
  22. 22.
    Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 2005;112:139–143.CrossRefPubMedGoogle Scholar
  23. 23.
    Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112:593–598.CrossRefPubMedGoogle Scholar
  24. 24.
    Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone. Arch Ophthalmol. 2004;122:336–340.CrossRefPubMedGoogle Scholar
  25. 25.
    Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87:24–27.CrossRefPubMedGoogle Scholar
  26. 26.
    Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138:740–743.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Yousuf Khalifa
    • 1
  • Sandra M. Johnson
    • 2
  1. 1.Moran Eye Institute, University of UtahSalt Lake CityUSA
  2. 2.Glaucoma Service, University of Virginia School of MedicineCharlottesvilleVAUSA

Personalised recommendations